{"id":13390,"date":"2024-08-23T00:21:56","date_gmt":"2024-08-22T22:21:56","guid":{"rendered":"https:\/\/valintermed.com\/?p=13390"},"modified":"2024-08-23T00:21:56","modified_gmt":"2024-08-22T22:21:56","slug":"sindrom-viskotta-oldricha","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/viskotta-oldricha-syndrome\/","title":{"rendered":"Wiskott-Aldrich syndrome"},"content":{"rendered":"
<\/div>\n

Wiskott-Aldrich syndrome (WAS) is a rare X-linked hereditary disease characterized by a combination of severe immunodeficiency, thrombocytopenia, and eczema. The disease is caused by mutations in the WAS (Wiskott-Aldrich Syndrome) gene, which is responsible for regulating the functions of platelets, leukocytes, and other cells of the immune system. Patients with the syndrome have increased susceptibility to infections, especially bacterial and viral, hemostatic disorders, and skin rashes. The pathogenesis of the disease includes not only platelet formation disorders (which leads to thrombocytopenia), but also changes in the function of T- and B-lymphocytes, which causes insufficient antibody production and cellular immune response. Thus, Wiskott-Aldrich syndrome is a multifactorial disease that requires a comprehensive approach to diagnosis and treatment.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n